41220 Federal Register / Vol. 71, No.

139 / Thursday, July 20, 2006 / Notices

Federal agencies, state and local professional associations, clinicians, total estimated annualized burden hours
governments, schools of public health, researchers, administrators, and health are 8,645.
colleges and universities, private planners. There are no costs to the
industry, nonprofit foundations, respondents other than their time. The

ESTIMATED ANNUALIZED BURDEN HOURS

Number of Avg. burden
Number of
Respondents responses/re- per response
respondents spondent (in hrs)

Office-based physicians (eligible):

Physician Induction Interview ............................................................................................... 2,662 1 35/60
Patient Record form ............................................................................................................. 2,263 30 5/60
Pulling and re-filing Patient Record form ............................................................................. 399 30 1/60
CCSS .................................................................................................................................... 712 1 15/60
Office-based physicians (ineligible):
Patient Induction Interview ................................................................................................... 888 1 5/60
Community Health Center Directors:
Community Health Center Induction Interview ..................................................................... 104 1 20/60
CHC Providers:
Physician Induction Interview ............................................................................................... 312 1 35/60
Patient Record Form ............................................................................................................ 265 30 5/60
Pulling and re-filing Patient Record form ............................................................................. 47 30 1/60
CCSS .................................................................................................................................... 312 1 15/60

Dated: July 11, 2006. Cicely.Reese@fda.hhs.gov, or FDA statement of the general nature of the
Joan F. Karr, Advisory Committee Information Line, evidence or arguments they wish to
Acting Reports Clearance Officer, Centers for 1–800–741–8138 (301–443–0572 in the present, the names and addresses of
Disease Control and Prevention. Washington, DC area), code proposed participants, and an
[FR Doc. E6–11521 Filed 7–19–06; 8:45 am] 3014512544. Please call the Information indication of the approximate time
BILLING CODE 4163–18–P Line for up-to-date information on this requested to make their presentation on
meeting. The background material will or before August 23, 2006.
become available no later than the day Persons attending FDA’s advisory
DEPARTMENT OF HEALTH AND before the meeting and will be posted committee meetings are advised that the
HUMAN SERVICES on FDA’s Web site at http:// agency is not responsible for providing
www.fda.gov/ohrms/dockets/ac/ access to electrical outlets.
Food and Drug Administration acmenu.htm under the heading FDA welcomes the attendance of the
‘‘Psychopharmacologic Drugs Advisory public at its advisory committee
Psychopharmacologic Drugs Advisory
Committee (PDAC).’’ (Click on the year meetings and will make every effort to
Committee; Notice of Meeting
2006 and scroll down to PDAC accommodate persons with physical
AGENCY: Food and Drug Administration, meetings.) disabilities or special needs. If you
HHS. Agenda: On September 7, 2006, the require special accommodations due to
ACTION: Notice. committee will discuss new drug a disability, please contact Cicely Reese
application (NDA) 21–999, paliperidone at least 7 days in advance of the
This notice announces a forthcoming extended-release (ER) tablets, Janssen,
meeting of a public advisory committee meeting.
L.P./Johnson & Johnson Pharmaceutical Notice of this meeting is given under
of the Food and Drug Administration Research and Development, L.L.C.,
(FDA). The meeting will be open to the the Federal Advisory Committee Act (5
proposed indication for treatment of U.S.C. app. 2).
public. schizophrenia. On September 8, 2006,
Name of Committee: Dated: July 13, 2006.
the committee will discuss NDA 21–
Psychopharmacologic Drugs Advisory Randall W. Lutter,
992, desvenlafaxine succinate (DVS
Committee. Associate Commissioner for Policy and
General Function of the Committee: 233), ER tablets, Wyeth
Pharmaceuticals, proposed indication Planning.
To provide advice and
for treatment of major depressive [FR Doc. E6–11537 Filed 7–19–06; 8:45 am]
recommendations to the agency on
FDA’s regulatory issues. disorder. BILLING CODE 4160–01–S

Date and Time: The meeting will be Procedure: Interested persons may
held on September 7 and 8, 2006, from present data, information, or views,
orally or in writing, on issues pending DEPARTMENT OF HEALTH AND
8 a.m. to 5 p.m.
Location: Hilton Hotel,The Ballrooms, before the committee. Written HUMAN SERVICES
620 Perry Pkwy., Gaithersburg, MD submissions may be made to the contact
person on or before August 23, 2006. Food and Drug Administration
20877.
Contact Person: Cicely Reese, Center Oral presentations from the public will Advisory Committee for Reproductive
rwilkins on PROD1PC63 with NOTICES_1

for Drug Evaluation and Research (HFD– be scheduled between approximately 1 Health Drugs; Notice of Meeting
21), Food and Drug Administration, p.m. and 2 p.m. on both days. Time
5600 Fishers Lane (for express delivery, allotted for each presentation may be AGENCY: Food and Drug Administration,
5630 Fishers Lane, rm. 1093) Rockville, limited. Those desiring to make formal HHS.
MD 20857, 301–827–7001, FAX: 301– oral presentations should notify the
ACTION: Notice.
827–6776, e-mail: contact person and submit a brief

VerDate Aug<31>2005 19:44 Jul 19, 2006 Jkt 208001 PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 E:\FR\FM\20JYN1.SGM 20JYN1